Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung D, Sutton R, White DL.

Br J Cancer. 2018 Apr;118(7):1000-1004. doi: 10.1038/s41416-018-0022-0. Epub 2018 Mar 13.

PMID:
29531323
2.

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Jones L, Richmond J, Evans K, Carol H, Jing D, Kurmasheva RT, Billups CA, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2017 Jul 15;23(14):3744-3755. doi: 10.1158/1078-0432.CCR-16-2392. Epub 2017 Jan 24.

PMID:
28119366
3.

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

Jones L, Carol H, Evans K, Richmond J, Houghton PJ, Smith MA, Lock RB.

Leukemia. 2016 Nov;30(11):2133-2141. doi: 10.1038/leu.2016.192. Epub 2016 Jul 15. Review.

PMID:
27416986
4.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26304. Epub 2016 Oct 27.

5.

Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.

Yadav BD, Samuels AL, Wells JE, Sutton R, Venn NC, Bendak K, Anderson D, Marshall GM, Cole CH, Beesley AH, Kees UR, Lock RB.

Oncotarget. 2016 Sep 13;7(37):58728-42. doi: 10.18632/oncotarget.11233.

6.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub 2016 Sep 12. No abstract available.

7.

A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.

El-Hoss J, Jing D, Evans K, Toscan C, Xie J, Lee H, Taylor RA, Lawrence MG, Risbridger GP, MacKenzie KL, Sutton R, Lock RB.

Oncotarget. 2016 Sep 13;7(37):60475-60490. doi: 10.18632/oncotarget.11125.

8.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ.

Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5.

9.

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, Billups CA, Erickson SW, Guo Y, Houghton PJ, Smith MA, Carol H, Roberts AW, Huang DC, Lock RB.

Blood. 2016 Sep 8;128(10):1382-95. doi: 10.1182/blood-2016-03-707414. Epub 2016 Jun 24.

10.

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.

Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM.

Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167.

11.

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, Carol H, Heatley S, Sutton R, Marshall GM, White D, Pimanda J, Houghton PJ, Smith MA, Lock RB.

Cancer Res. 2016 Aug 1;76(15):4579-91. doi: 10.1158/0008-5472.CAN-16-0523. Epub 2016 Jun 14.

12.

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

Trahair TN, Lock RB, Sutton R, Sia KC, Evans K, Richmond J, Law T, Venn NC, Irving JA, Moore S, Nievergall E, Dang P, Heatley SL, White DL, Revesz T.

Bone Marrow Transplant. 2016 Sep;51(9):1279-82. doi: 10.1038/bmt.2016.122. Epub 2016 May 16. No abstract available.

PMID:
27183096
13.

Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG.

JCI Insight. 2016;1(4). pii: e86082. Epub 2016 Apr 7.

14.

MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Huang Y, Thoms JA, Tursky ML, Knezevic K, Beck D, Chandrakanthan V, Suryani S, Olivier J, Boulton A, Glaros EN, Thomas SR, Lock RB, MacKenzie KL, Bushweller JH, Wong JW, Pimanda JE.

Leukemia. 2016 Jul;30(7):1552-61. doi: 10.1038/leu.2016.55. Epub 2016 Mar 8.

15.

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

Dolai S, Sia KC, Robbins AK, Zhong L, Heatley SL, Vincent TL, Hochgräfe F, Sutton R, Kurmasheva RT, Revesz T, White DL, Houghton PJ, Smith MA, Teachey DT, Daly RJ, Raftery MJ, Lock RB.

Cancer Res. 2016 Mar 9. pii: canres.2786.2015. [Epub ahead of print]

PMID:
26960974
16.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006. Erratum in: Cancer Cell. 2016 Sep 12;30(3):499-500.

17.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24.

18.

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.

Shahbazi J, Liu PY, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, Liu T.

Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.

19.

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW.

Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.

20.

p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.

Davies C, Hogarth LA, Mackenzie KL, Hall AG, Lock RB.

Cell Cycle. 2015;14(22):3602-12. doi: 10.1080/15384101.2015.1100774.

21.

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.

Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, Wei A, Ramshaw HS, Powell JA, Lopez AF, Lewis ID, McCall MN, Lock RB.

Haematologica. 2015 Jul;100(7):914-26. doi: 10.3324/haematol.2014.113092.

22.

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, Kurmasheva RT, Billups C, Houghton PJ, Smith MA, Carol H, Lock RB.

Blood. 2015 Sep 3;126(10):1193-202. doi: 10.1182/blood-2014-12-618900. Epub 2015 Jun 26.

23.

Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.

Toscan CE, Rahimi M, Bhadbhade M, Pickford R, McAlpine SR, Lock RB.

Org Biomol Chem. 2015 Jun 14;13(22):6299-312. doi: 10.1039/c5ob00779h.

PMID:
25967739
24.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.

Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.

25.

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.

Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A, Meyer C, Venn NC, Marschalek R, Henderson M, Sutton R, Kurmasheva RT, Kees UR, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2015 Mar 15;21(6):1395-405. doi: 10.1158/1078-0432.CCR-14-2300. Epub 2015 Jan 8.

26.

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Farhang Ghahremani M, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Canté-Barrett K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JP, Soulier J, Van Vlierberghe P, Haigh JJ.

Nat Commun. 2015 Jan 7;6:5794. doi: 10.1038/ncomms6794.

27.

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.

Suryani S, Bracken LS, Harvey RC, Sia KC, Carol H, Chen IM, Evans K, Dietrich PA, Roberts KG, Kurmasheva RT, Billups CA, Mullighan CG, Willman CL, Loh ML, Hunger SP, Houghton PJ, Smith MA, Lock RB.

Mol Cancer Ther. 2015 Feb;14(2):364-74. doi: 10.1158/1535-7163.MCT-14-0647. Epub 2014 Dec 10.

28.

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ.

Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119.

29.

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW.

Cell Stem Cell. 2014 Dec 4;15(6):775-90. doi: 10.1016/j.stem.2014.11.010.

30.

Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.

Nowak D, Liem NL, Mossner M, Klaumünzer M, Papa RA, Nowak V, Jann JC, Akagi T, Kawamata N, Okamoto R, Thoennissen NH, Kato M, Sanada M, Hofmann WK, Ogawa S, Marshall GM, Lock RB, Koeffler HP.

Exp Hematol. 2015 Jan;43(1):32-43.e1-35. doi: 10.1016/j.exphem.2014.09.007. Epub 2014 Oct 29.

31.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. doi: 10.1002/pbc.25329. Epub 2014 Nov 18.

32.

Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.

Jing D, Bhadri VA, Beck D, Thoms JA, Yakob NA, Wong JW, Knezevic K, Pimanda JE, Lock RB.

Blood. 2015 Jan 8;125(2):273-83. doi: 10.1182/blood-2014-05-576470. Epub 2014 Oct 21.

33.

Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.

Tursky ML, Beck D, Thoms JA, Huang Y, Kumari A, Unnikrishnan A, Knezevic K, Evans K, Richards LA, Lee E, Morris J, Goldberg L, Izraeli S, Wong JW, Olivier J, Lock RB, MacKenzie KL, Pimanda JE.

Leukemia. 2015 Apr;29(4):819-27. doi: 10.1038/leu.2014.299. Epub 2014 Oct 13.

PMID:
25306899
34.

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.

Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P, Smith MA, Lock RB.

Pediatr Blood Cancer. 2015 Jan;62(1):65-71. doi: 10.1002/pbc.25133. Epub 2014 Sep 9.

35.

High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.

Toscan CE, Failes T, Arndt GM, Lock RB.

J Biomol Screen. 2014 Dec;19(10):1391-401. doi: 10.1177/1087057114546550. Epub 2014 Aug 7.

PMID:
25104793
36.

A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.

Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB.

Blood Cancer J. 2014 Aug 1;4:e232. doi: 10.1038/bcj.2014.52.

37.

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.

Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2014 Sep 1;20(17):4520-31. doi: 10.1158/1078-0432.CCR-14-0259. Epub 2014 Jul 10.

38.

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T.

Oncotarget. 2014 Jun 30;5(12):4257-68.

39.

Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.

Wong NC, Bhadri VA, Maksimovic J, Parkinson-Bates M, Ng J, Craig JM, Saffery R, Lock RB.

BMC Genomics. 2014 Jun 1;15:416. doi: 10.1186/1471-2164-15-416.

40.

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.

Leukemia. 2014 Nov;28(11):2213-21. doi: 10.1038/leu.2014.128. Epub 2014 Apr 7.

PMID:
24705479
41.

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.

Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D.

Pediatr Blood Cancer. 2014 Aug;61(8):1493-6. doi: 10.1002/pbc.25026. Epub 2014 Mar 24. Erratum in: Pediatr Blood Cancer. 2014 Sep;61(9):1716. Lyalin, Dmitry [added].

42.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, Smaill JB, Patterson AV, Mulaw MA, Konopleva M, Bohlander SK, Lock RB, Wilson WR.

Biochem Pharmacol. 2014 Mar 1;88(1):36-45. doi: 10.1016/j.bcp.2013.12.019. Epub 2014 Jan 13.

PMID:
24434189
43.

Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.

Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW.

Cell Rep. 2013 Nov 27;5(4):1047-59. doi: 10.1016/j.celrep.2013.10.038. Epub 2013 Nov 21.

44.

Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.

Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M.

Ann Hematol. 2014 Mar;93(3):485-492. doi: 10.1007/s00277-013-1939-2. Epub 2013 Oct 24.

45.

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA.

Blood. 2013 Aug 1;122(5):738-48. doi: 10.1182/blood-2012-08-447441. Epub 2013 Jun 17.

46.

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.

Neoplasia. 2013 May;15(5):511-22.

47.

Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress.

Kan CY, Petti C, Bracken L, Maritz M, Xu N, O'Brien R, Yang C, Liu T, Yuan J, Lock RB, MacKenzie KL.

J Biol Chem. 2013 Apr 26;288(17):12032-41. doi: 10.1074/jbc.M112.447821. Epub 2013 Feb 28.

48.

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2013 Apr 1;19(7):1795-805. doi: 10.1158/1078-0432.CCR-12-3613. Epub 2013 Feb 20. Erratum in: Clin Cancer Res. 2013 Jun 1;19(11):3108.

49.

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.

Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Jul;60(7):E42-5. doi: 10.1002/pbc.24451. Epub 2013 Jan 9.

50.

Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia.

Oram SH, Thoms J, Sive JI, Calero-Nieto FJ, Kinston SJ, Schütte J, Knezevic K, Lock RB, Pimanda JE, Göttgens B.

Leukemia. 2013 Jun;27(6):1348-57. doi: 10.1038/leu.2013.2. Epub 2013 Jan 10.

Supplemental Content

Support Center